PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26366172-7 2015 Administration of ipragliflozin, a selective inhibitor of sodium-glucose cotransporter 2, in the mouse model of repetitive glucose spikes inhibited the progression of atherosclerosis, whereas long-term repetitive glucose spikes, repetitive hypoglycaemia, and their combination had no significant impact on atherosclerosis. ipragliflozin 18-31 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 58-88 22139434-0 2012 Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. ipragliflozin 27-40 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 70-75 23707905-2 2013 In the present study, the therapeutic effects of SGLT2 selective inhibitor ipragliflozin were examined in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice which exhibit impaired insulin secretion, insulin resistance, hyperlipidemia, hepatic steatosis, and obesity. ipragliflozin 75-88 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 49-54 23707905-6 2013 These results demonstrate that SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also diabetes/obesity-associated metabolic abnormalities in type 2 diabetic mice and suggest that ipragliflozin may be useful in treating type 2 diabetes with metabolic syndrome. ipragliflozin 57-70 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 31-36 23707905-6 2013 These results demonstrate that SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also diabetes/obesity-associated metabolic abnormalities in type 2 diabetic mice and suggest that ipragliflozin may be useful in treating type 2 diabetes with metabolic syndrome. ipragliflozin 205-218 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 31-36 22507206-3 2012 Through further optimization of 14a, a novel benzothiophene derivative (14h; ipragliflozin, ASP1941) was discovered as a highly potent and selective SGLT2 inhibitor that reduced blood glucose levels in a dose-dependent manner in diabetic models KK-A(y) mice and STZ rats. ipragliflozin 77-90 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 149-154 22507206-3 2012 Through further optimization of 14a, a novel benzothiophene derivative (14h; ipragliflozin, ASP1941) was discovered as a highly potent and selective SGLT2 inhibitor that reduced blood glucose levels in a dose-dependent manner in diabetic models KK-A(y) mice and STZ rats. ipragliflozin 92-99 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 149-154 22139434-0 2012 Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. ipragliflozin 42-49 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 70-75 22139434-2 2012 In vitro, the potency of ipragliflozin to inhibit SGLT2 and SGLT1 and stability were assessed. ipragliflozin 25-38 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 50-55 22139434-4 2012 Ipragliflozin potently and selectively inhibited human, rat, and mouse SGLT2 at nanomolar ranges and exhibited stability against intestinal glucosidases. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 71-76 22139434-9 2012 These results suggest that ipragliflozin is an orally active SGLT2 selective inhibitor that induces sustained increases in urinary glucose excretion by inhibiting renal glucose reabsorption, with subsequent antihyperglycemic effect and a low risk of hypoglycemia. ipragliflozin 27-40 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 61-66 32821334-4 2020 The SGLT2 inhibitor ipragliflozin has reportedly improved liver steatosis in animal models and clinical studies. ipragliflozin 20-33 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 4-9 34298949-2 2021 We determined whether changes in perirenal fat (PRAT) by a SGLT2 inhibitor ipragliflozin (Ipra) contribute to the suppression of DN development. ipragliflozin 75-88 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 59-64 34298949-2 2021 We determined whether changes in perirenal fat (PRAT) by a SGLT2 inhibitor ipragliflozin (Ipra) contribute to the suppression of DN development. ipragliflozin 90-94 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 59-64 33611885-0 2021 Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/SIRT1 Pathway. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 18-23 33611885-3 2021 Therefore, we investigated the effect of ipragliflozin (a selective SGLT2 inhibitor) on energy metabolism. ipragliflozin 41-54 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 68-73 33611885-10 2021 Conclusion: SGLT2 inhibition by ipragliflozin showed beneficial metabolic effects in 129S6/Sv mice with HFD-induced obesity that mimics prediabetic conditions. ipragliflozin 32-45 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 12-17 22971845-0 2012 Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. ipragliflozin 50-63 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 24-29 22971845-2 2012 The present study investigated the antidiabetic effects of ipragliflozin, a SGLT2-selective inhibitor, in streptozotocin-nicotinamide-induced mildly diabetic mice, which exhibited a mild decline in glucose tolerance associated with the loss of early-phase insulin secretion. ipragliflozin 59-72 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 76-81 22971845-5 2012 These results suggest that the SGLT2-selective inhibitor ipragliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption, improves hyperglycemia in streptozotocin-nicotinamide-induced mildly diabetic mice, and may be useful for treating type 2 diabetes. ipragliflozin 57-70 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 31-36 34487707-0 2021 SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice. ipragliflozin 16-29 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 0-5 34487707-1 2021 This study investigated the antihyperglycemic effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin via the blood glucose-dependent increase in urinary glucose excretion in KK/Ay type 2 diabetic mice. ipragliflozin 110-123 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 61-91 34487707-1 2021 This study investigated the antihyperglycemic effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin via the blood glucose-dependent increase in urinary glucose excretion in KK/Ay type 2 diabetic mice. ipragliflozin 110-123 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 93-98 34494293-0 2022 SGLT2 inhibitor ipragliflozin poses a low risk of hypoglycemia owing to its blood glucose-dependent urinary glucose excretion mechanism in mice. ipragliflozin 16-29 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 0-5 34494293-2 2022 This study examined the effects of the SGLT2 inhibitor ipragliflozin on blood glucose-dependent urinary glucose excretion in mice. ipragliflozin 55-68 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 39-44 35192632-2 2022 The sodium glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin was developed as a new oral hypoglycemic drug, which can improve NASH via an insulin-independent glucose-lowering effect by inhibiting glucose reabsorption in the renal proximal tubules. ipragliflozin 53-66 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 4-34 35192632-2 2022 The sodium glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin was developed as a new oral hypoglycemic drug, which can improve NASH via an insulin-independent glucose-lowering effect by inhibiting glucose reabsorption in the renal proximal tubules. ipragliflozin 53-66 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 36-41 33015603-2 2020 Objective: We aimed to explore whether SGLT2 inhibitor ipragliflozin has a direct reno-protective effect on non-diabetic chronic kidney disease (CKD) in mice. ipragliflozin 55-68 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 39-44 29352520-13 2018 Suppression of SGLT2 by a specific small interfering ribonucleic acid or ipragliflozin restored these GTPase levels to their normal values. ipragliflozin 73-86 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 15-20 31955626-0 2020 Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. ipragliflozin 39-52 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 23-28 31955626-4 2020 Here, we investigated the therapeutic effects of the SGLT2 selective inhibitor ipragliflozin alone and in combination with metformin on NASH in high fat and cholesterol diet-fed KK/Ay type 2 diabetic mice.Results: This diabetic model had hyperglycemia, insulin resistance, and obesity, and also exhibited steatosis, inflammation, and fibrosis in the liver, pathological features resembling those in human NASH. ipragliflozin 79-92 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 53-58 31955626-8 2020 In addition, combination treatment with ipragliflozin and metformin additively improved these symptoms.Conclusions: These results demonstrate that the SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also NASH in type 2 diabetic mice, suggesting that treatment with ipragliflozin alone and in combination with metformin may be effective for treating type 2 diabetes with NASH. ipragliflozin 40-53 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 151-156 31955626-8 2020 In addition, combination treatment with ipragliflozin and metformin additively improved these symptoms.Conclusions: These results demonstrate that the SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also NASH in type 2 diabetic mice, suggesting that treatment with ipragliflozin alone and in combination with metformin may be effective for treating type 2 diabetes with NASH. ipragliflozin 177-190 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 151-156 31955626-8 2020 In addition, combination treatment with ipragliflozin and metformin additively improved these symptoms.Conclusions: These results demonstrate that the SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also NASH in type 2 diabetic mice, suggesting that treatment with ipragliflozin alone and in combination with metformin may be effective for treating type 2 diabetes with NASH. ipragliflozin 177-190 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 151-156 31888083-5 2019 We aimed to investigate the role of ELD and ER stress in the development of CKD, and evaluate the efficacy of a sodium glucose cotransporter-2 inhibitor, ipragliflozin. ipragliflozin 154-167 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 112-142 31782258-0 2019 SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. ipragliflozin 16-29 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 0-5 31782258-11 2019 These findings indicate that the SGLT2-selective inhibitor ipragliflozin improves hyperglycemia as well as NASH in type 2 diabetic mice. ipragliflozin 59-72 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 33-38 31234839-11 2019 CONCLUSIONS: The Ipra-induced changes of abdominal PVAT will lead to a better understanding of unveiled mechanisms by which SGLT2 inhibitors prevent cardiovascular complications in T2DM, and the development of new therapeutic strategies targeting PVAT. ipragliflozin 17-21 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 124-129 30914436-8 2019 Ipragliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, lowered PKC activity in distal convoluted tubule cells and reduced KLHL3S433-P and NCC levels, whereas the thiazolidinedione pioglitazone did not, although the two agents similarly reduced in blood glucose levels. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 17-47 30914436-8 2019 Ipragliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, lowered PKC activity in distal convoluted tubule cells and reduced KLHL3S433-P and NCC levels, whereas the thiazolidinedione pioglitazone did not, although the two agents similarly reduced in blood glucose levels. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 49-54 30021338-9 2018 SIGNIFICANCE: These results indicate that the SGLT2 inhibitor, ipragliflozin, exerts antihyperglycemic actions by increasing urinary glucose excretion, and induces weight loss without a compensatory increase in food intake in type 2 diabetic mice. ipragliflozin 63-76 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 46-51 29507299-6 2018 Regarding renal tissue hypoxia, a short-term ipragliflozin treatment improved oxygen tension in the kidney cortex, in which SGLT2 is predominantly expressed. ipragliflozin 45-58 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 124-129 29374293-0 2018 Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. ipragliflozin 31-44 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 15-20 29374293-3 2018 We examined the therapeutic effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and the progression of nephropathy in uninephrectomized type 2 diabetic mice, which exhibit not only typical diabetic symptoms, such as impaired insulin secretion, glucose intolerance, hyperglycemia, and obesity, but also overt nephropathy with decline in renal function. ipragliflozin 59-72 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 43-48 29425766-0 2018 Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents. ipragliflozin 40-53 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 24-29 29425766-2 2018 Here, we investigated whether or not dietary carbohydrate content affects the efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in type 2 diabetic mice. ipragliflozin 143-156 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 126-131 29702076-0 2018 Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. ipragliflozin 73-86 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 57-62 29702076-7 2018 These results suggest that the SGLT2 inhibitor ipragliflozin prevents progression to diabetic overt nephropathy in uninephrectomized type 2 diabetic mice. ipragliflozin 47-60 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 31-36 26731267-0 2016 The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. ipragliflozin 30-43 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 14-19 29154936-0 2018 Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution. ipragliflozin 56-69 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 40-45 29154936-3 2018 Here, we investigated the possible effects of sugar solution intake on the antidiabetic effects of sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in type 2 diabetic mice that were fed ordinary drinking water, water + glucose solution, or water + sucrose solution. ipragliflozin 148-161 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 131-136 29154936-9 2018 Our observation that the antidiabetic and antiobesity effects of the SGLT2 inhibitor ipragliflozin were not greatly affected by sugar solution intake in type 2 diabetic mice suggests that, in a clinical setting, ipragliflozin will remain an effective treatment for type 2 diabetic patients with excessive intake of carbohydrates. ipragliflozin 85-98 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 69-74 27833913-0 2016 Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. ipragliflozin 22-35 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 55-60 27833913-2 2016 Ipragliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, offers a novel approach for the treatment of diabetes by enhancing urinary glucose excretion. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 27-57 27833913-2 2016 Ipragliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, offers a novel approach for the treatment of diabetes by enhancing urinary glucose excretion. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 59-64 26450351-0 2016 Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. ipragliflozin 56-69 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 30-35 26450351-2 2016 In the present study, the combinatory effects of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice were investigated. ipragliflozin 75-88 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 49-54 28506912-4 2017 While all SGLT2 inhibitors exerted comparable effects in reducing hyperglycemia, improvement of these diabetes-related diseases and complications was more potent with the two long-acting drugs (ipragliflozin and dapagliflozin) than with the four intermediate-acting four drugs (tofogliflozin, canagliflozin, empagliflozin, and luseogliflozin), albeit without statistical significance. ipragliflozin 194-207 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 10-15 27327650-3 2016 We conducted an 8-week study using non-diabetic mice, which were fed ad-libitum with LCHD or a normal carbohydrate diet (NCHD) and treated with/without the SGLT-2 inhibitor, ipragliflozin. ipragliflozin 174-187 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 156-162 26977813-5 2016 Here we show that an SGLT2 inhibitor ipragliflozin improves hepatic steatosis in high-fat diet-induced and leptin-deficient (ob/ob) obese mice irrespective of body weight reduction. ipragliflozin 37-50 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 21-26